<DOC>
	<DOCNO>NCT00003544</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness irinotecan treating patient metastatic colorectal cancer .</brief_summary>
	<brief_title>Irinotecan Treating Patients With Metastatic Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate clinical usefulness preoperative irinotecan patient high risk , technically resectable metastatic colorectal cancer refractory fluorouracil . II . Evaluate prospectively relationship expression select molecular determinant response clinical responsiveness irinotecan patient . III . Determine effect treatment irinotecan expression putative response determinant patient . OUTLINE : This open label study . Patients receive irinotecan IV 90 minute weekly 4 consecutive week . Course repeat every 6 week . After 2 course , CT scan obtain patient show evidence disease still amenable surgical resection undergo surgery . Approximately 4-8 week surgical resection , patient receive 3 additional course irinotecan absence disease progression unacceptable toxicity . Patients follow every 3 month 2 year every 6 month year 3 4 . PROJECTED ACCRUAL : A total 30 patient accrue study .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm technically resectable metastatic colorectal cancer high risk relapse Must meet one follow criterion : Metastatic colorectal cancer confine liver plus portal lymph node Recurrent metastatic colorectal cancer confine liver first hepatic resection Metastatic colorectal cancer confine lung plus liver Metastatic colorectal cancer confine liver MSKCC risk factor score great 4 Metastatic colorectal cancer confine lung , either great 1 nodule and/or less 3 year disease free survival Metastatic colorectal cancer confine ovary Metastatic colorectal cancer confine single intraabdominal lymph node Must fail fluorouracilbased chemotherapy metastatic disease , receive fluorouracilbased chemotherapy adjuvant setting , tumor measure thymidylate synthase level great 4.0 , lung metastasis PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : WBC least 3,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin le 1.5 mg/dL Renal : Creatinine le 2.0 mg/dL Cardiovascular : No myocardial infarction last 6 month Other : No prior malignancy past 5 year except adequately treat basal cell squamous cell skin cancer carcinoma situ cervix No active uncontrolled infection No psychiatric disorder No concurrent disease would preclude entry study Not pregnant nursing Effective contraception require fertile patient PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics No prior irinotecan camptothecins Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
</DOC>